Abstract:The Keap1 (Kelch-like ECH-associated protein 1)-Nrf2 (nuclear factor erythroid 2-related factor 2)-ARE (antioxidant response element) pathway is the major defending mechanism against oxidative stresses, and directly disrupting the Keap1-Nrf2 protein–protein interaction (PPI) has been an attractive strategy to target oxidative stress-related diseases, including cardiovascular diseases. Here, we describe the design, synthesis, and structure–activity relationships (SARs) of indoline-based compounds as potent Keap1-Nrf2 PPI inhibitors. Comprehensive SAR analysis and thermodynamics-guided optimization identified 19a as the most potent inhibitor in this series, with an IC50 of 22 nM in a competitive fluorescence polarization assay. Further evaluation indicated the proper drug-like properties of 19a. Compound 19a dose-dependently upregulated genes and protein level of Nrf2 as well as its downstream markers and showed protective effects against lipopolysaccharide-induced injury in both H9c2 cardiac cells and mouse models. Collectively, we reported here a novel indoline-based Keap1-Nrf2 PPI inhibitor as a potential cardioprotective agent.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01116?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01116</a>.Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01116/suppl_file/jm0c01116_si_001.csv">CSV</a>)Characterization of the representative intermediates, characterization of the target compounds, Keap1 Kelch domain expression and purification, FP competition assay, binding mode of compound 15 with Keap1, determination of thermodynamic data based on tracer displacement assay, ITC assay, BLI assay, ARE-luciferase activity assay, cell viability assay, RNA extraction and qRT-PCR analysis, Western blot analysis, IL-1β, IL-6, and TNF-α production, evaluation of GSH/GSSG ratio, detection of ROS level, animal experiments, statistical analysis and 1H NMR, 13C NMR, HRMS and HPLC spectra for representative target compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01116/suppl_file/jm0c01116_si_002.pdf">PDF</a>)This article has not yet been cited by other publications.

Discovery of novel 5-phenyl-1H-pyrrole-2-carboxylic acids as Keap1-Nrf2 inhibitors for acute lung injury treatment

Structure-based molecular hybridization design of Keap1-Nrf2 inhibitors as novel protective agents of acute lung injury

Fragment-Based Discovery of Azocyclic Alkyl Naphthalenesulfonamides as Keap1-Nrf2 Inhibitors for Acute Lung Injury Treatment

MitoQ Protects Against Hyperpermeability of Endothelium Barrier in Acute Lung Injury Via a Nrf2-dependent Mechanism

Cyclic Peptide Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Design, Synthesis, and In Vivo Treatment of Acute Lung Injury

Discovery of Propionic Acid Derivatives with a 5-THIQ Core as Potent and Orally Bioavailable Keap1-Nrf2 Protein-Protein Interaction Inhibitors for Acute Kidney Injury

Discovery of 2-Oxy-2-phenylacetic Acid Substituted Naphthalene Sulfonamide Derivatives As Potent KEAP1-NRF2 Protein-Protein Interaction Inhibitors for Inflammatory Conditions.

Discovery of disubstituted xylylene derivatives as small molecule direct inhibitors of Keap1-Nrf2 protein-protein interaction

Design, Synthesis, and Structure–Activity Relationships of Indoline-Based Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-Like 2 (Keap1-Nrf2) Protein–Protein Interaction Inhibitors

4-Indole-2-arylaminopyrimidine Identifies Lysosomal Cathepsin L Activation Critical for Acute Lung Injury

Targeting Keap1 with Inulae Herba activated the Nrf2 receptor to alleviate LPS-mediated acute lung injury

Evidence that a Novel Chalcone Derivative, Compound 27, Acts on the Epithelium Via the PI3K/AKT/Nrf2-Keap1 Signaling Pathway, to Mitigate LPS-Induced Acute Lung Injury in Mice

Inhibition of Cathepsin L Ameliorates Inflammation Through the A20/NF-κB Pathway in Endotoxin-Induced Acute Lung Injury

Discovery of the Specific Inhibitory Effect of Thiamphenicol on LPS-induced Acute Lung Injury (ALI) in Mice Through Virtual Screening and Biological Evaluation

Mechanism and Experimental Verification of Rhodiola rosea L. for the Treatment of Acute Lung Injury Through Network Pharmacology and Molecular Docking

Design, synthesis, and bioactivity evaluation of novel 1-(4-(benzylsulfonyl)-2-nitrophenyl) derivatives as potential anti-inflammatory agents against LPS-induced acute lung injury

Structure-Activity and Structure-Property Relationship and Exploratory in Vivo Evaluation of the Nanomolar Keap1-Nrf2 Protein-Protein Interaction Inhibitor

A Melanin-like Nanoenzyme for Acute Lung Injury Therapy via Suppressing Oxidative and Endoplasmic Reticulum Stress Response

Physalin H ameliorates LPS-induced acute lung injury via KEAP1/NRF2 axis

Structure-activity and structure-property relationships of novel Nrf2 activators with a 1,2,4-oxadiazole core and their therapeutic effects on acetaminophen (APAP)-induced acute liver injury.

Protective Effects of Kirenol against Lipopolysaccharide-Induced Acute Lung Injury through the Modulation of the Proinflammatory NFκB Pathway and the AMPK2-/Nrf2-Mediated HO-1/AOE Pathway